Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
BC Partners Lending Corp reported total investment income of $16.9 million for the nine months ended September 30, 2026, compared to $14.2 million in the prior year period. The company experienced a net decrease in net assets resulting from operations of $1.8 million for the nine-month period, primarily driven by $8.5 million in net realized and unrealized losses which offset $6.7 million in net investment income.
Fractyl Health reported Q3 2026 financial results and announced a major strategic pivot to focus on its Revita program, including a 45% workforce reduction and the discontinuation of internal Rejuva development. The company reported positive six-month pivotal data from its REMAIN-1 trial and plans to submit an FDA De Novo marketing application in late Q4 2026.
Term
Q3 2026
“There are approximately 1 million Americans discontinuing GLP-1s each month, and these individuals are at high risk of weight and metabolic rebound. In this context, we believe the positive pivotal results from REMAIN-1 represent a defining moment for Fractyl. In the most rigorous stress test we could conceive, a single Revita procedure met its six-month co-primary endpoint with high statistical significance.”
Harith Rajagopalan, M.D., Ph.D., Co-Founder, President and Chief Executive Officer
“Armed with positive data, we have focused the Company around Revita’s post-GLP-1 weight maintenance opportunity. We expect the capital we have today to be sufficient to fund our planned De Novo submission and upcoming 12-month pivotal data and. Our goal is for Revita to potentially establish an entirely new therapeutic category of post-GLP-1 weight maintenance by aiming to reverse years of diet-induced damage to the gut.”
Harith Rajagopalan, M.D., Ph.D., Co-Founder, President and Chief Executive Officer
Candel Therapeutics reported third quarter 2026 financial results, ending the period with $203.1 million in cash which is expected to fund operations into Q2 2028. The company updated its regulatory timeline, now planning to submit a Biologics License Application (BLA) for aglatimagene in prostate cancer in mid-2027 following assay refinement. Recent clinical progress included three poster presentations at the SITC 41st Annual Meeting showcasing data across its prostate, lung, and glioma programs.
Term
Q3 2026
“During the quarter we continued to execute well and make significant progress across the business, as we build the foundation to potentially become a commercial-stage biopharma company.”
Paul Peter Tak, M.D., Ph.D., FMedSci, President and CEO
“On the clinical side, we were honored to have had three posters accepted for presentation at SITC, featuring data on aglatimagene in localized prostate cancer and non-small cell lung cancer, and linoserpaturev in recurrent high-grade glioma. Together, the new biomarker data provide mechanistic support for the systemic effect and long-term clinical outcomes observed in our phase 3 trial of aglatimagene in patients with intermediate- to high-risk localized prostate cancer.”
Paul Peter Tak, M.D., Ph.D., FMedSci, President and CEO
BioStem Technologies reported Q3 2026 financial results, highlighting sequential hospital revenue growth to $6.8 million and increased customer penetration. The company raised its full-year 2026 revenue guidance and is finalizing a cost reduction plan to reduce annualized cash operating expenses by $10-$12 million.
Term
Q3 2026
“We grew hospital revenue again this quarter, and importantly, are doing so by adding new accounts and increasing penetration with existing customers. The number of customers buying two or more of our product lines grew 14% from the second quarter. We also completed the final step of our commercial infrastructure build-out, and with in-house production of Neox and Clarix expected to begin in the first half of 2027, we are on track to become a fully vertically integrated company with those product lines.”
Jason Matuszewski, Chair and CEO of BioStem
“With these foundations in place, we are focused on strengthening the balance sheet, raising our gross margin, reducing operating expenses and narrowing our adjusted EBITDA loss as we work toward breakeven.”
Hour Loop reported Q3 2026 financial results with net revenues of $32.1 million, a 4% decrease year-over-year, and net income of $0.4 million. The company narrowed its full-year 2026 guidance and highlighted its transition to an AI-first operating model to drive efficiency in purchasing and customer service.
Term
Q3 2026
“Through the first nine months of 2026, Hour Loop grew net revenues 11% and earned $2.3 million in net income, and we stayed profitable through a tougher third quarter. We made a deliberate choice to protect our margins rather than chase low-quality sales, and we believe that discipline puts us in a strong position as we head into the holiday season, the most important time of our year.”
Sam Lai, Chief Executive Officer and Interim Chief Financial Officer
“We are building an AI-first company, and AI is already changing how we work every day. AI agents now support core parts of our operations – purchasing and replenishment, advertising, pricing, inbound shipments, inventory reconciliation, customer service and compliance.”
Sam Lai, Chief Executive Officer and Interim Chief Financial Officer
Talphera reported a Q3 2026 net loss of $4.0 million and ended the quarter with $14.2 million in cash and investments. The company has submitted a briefing document to the FDA requesting to close enrollment for its pivotal NEPHRO CRRT study by year-end 2026, citing that current enrollment provides over 80% statistical power for the primary endpoint.
“We believe nafamostat has the potential to address an important unmet need as a regional anticoagulant for critically ill patients undergoing CRRT. Our updated market research, including physician feedback on nafamostat compared with currently used products, supports its potential adoption in CRRT and an increased peak sales estimate of more than $200 million.”
Vince Angotti, CEO of Talphera
“To date, we have enrolled more than 75% of the planned 70 patients. To support our goal of completing the study this year, we have submitted a briefing document to the FDA seeking feedback on closing enrollment as of December 31, 2026, even if fewer than the targeted 70 patients are enrolled. While the study remains blinded and open for enrollment, we believe the current enrollment is sufficient to support a PMA filing as it has over 80% statistical power for the primary endpoint.”
LuxExperience B.V CEO Michael Kliger Sells $400K of Stock
Michael Kliger, CEO, sold 38,412 shares of LuxExperience B.V. at $10.41 a share, worth $400K in total on Nov 10, 2026. Shares held after the trade: 0 (-100.0%).
Alnylam Pharmaceuticals Insider Charles Elliott Sigal Buys $244K of Stock
Charles Elliott Sigal bought 1,600 shares of Alnylam Pharmaceuticals, Inc. at $152.25 a share, worth $244K in total on Nov 10, 2026. Shares held after the trade: 3,600 (+80.0%).
GoPro entered into an amendment to its existing merger agreement with Action Acquisition LLC, extending the deal's outside closing date from December 31, 2026, to March 31, 2027. The amendment also includes technical adjustments for potential stock splits or reclassifications and corrects a scrivener's error regarding the parent company's name. Parent is required to seek an extension of its financing commitment letter to match the new March 2027 deadline.
Atlanta Braves Holdings EVP, Development Michael P. Plant Sells $9.66M of Stock
Michael P. Plant, EVP, Development, sold 186,588 shares of Atlanta Braves Holdings, Inc. at $51.28 to $52.21 a share (average $51.78) in 4 transactions, worth $9.66M in total between Nov 9, 2026 and Nov 11, 2026. Shares held after the trade: 0 (-100.0%).
Blend Labs Head of Blend Nima Ghamsari Sells $24.6K of Stock
Nima Ghamsari, Head of Blend, sold 25,511 shares of Blend Labs, Inc. at $0.965 a share, worth $24.6K in total on Nov 9, 2026. Shares held after the trade: 7,681,492 (-0.3%).
Marex Group Insider Paolo Tonucci Sells $1.14M of Stock
Paolo Tonucci sold 16,668 shares of Marex Group Ltd at $67.89 to $69.41 a share (average $68.68) in 3 transactions, worth $1.14M in total on Nov 9, 2026. Shares held after the trade: 1,236,237 (-0.2%).
Grid Dynamics Holdings Insider Shuo Zhang Sells $138K of Stock
Shuo Zhang sold 10,000 shares of Grid Dynamics Holdings, Inc. at $13.84 a share, worth $138K in total on Nov 11, 2026. Shares held after the trade: 94,772 (-9.5%).
Runway Growth Finance Co-CEO Michael Rovner Buys $49.7K of Stock
Michael Rovner, Co-CEO, bought 7,500 shares of Runway Growth Finance Corp. at $6.63 a share, worth $49.7K in total on Nov 11, 2026. Shares held after the trade: 14,500 (+107.1%).
Beeline Holdings reported Q3 2026 revenue of $3.0 million, a 30% year-over-year increase, while narrowing its net loss to $3.8 million. The company highlighted a shift toward higher-margin mortgage products and announced that definitive agreements for its acquisition of TYTL are expected to be signed within days. To reduce dilution, the CEO has agreed to forfeit 3 million of the 9 million merger shares he is slated to receive upon the closing of the TYTL deal.
Term
Q3 2026
“Despite challenging market conditions, our third quarter reflects measurable progress in the core business. Revenue grew 30% year-over-year while operating expenses declined sequentially. We are focusing on higher-margin mortgage products, improved conversion and AI-enabled efficiency. We remain disciplined about liquidity and cost reduction as we work toward a more scalable operating model.”
Assembly Biosciences reported Q3 2026 financial results and announced the receipt of a $75 million collaboration extension fee from Gilead Sciences, extending its cash runway into 2029. The company also exercised its option to share 40% of U.S. development costs and profits for the HSV helicase primase inhibitor program and initiated a Phase 2 study for ABI-6250 in chronic hepatitis delta virus.
Counterparty
Gilead Sciences, Inc.
“This quarter, we rapidly advanced our liver disease program by initiating the Phase 2 study of ABI-6250 in chronic hepatitis delta virus and preparing for our Phase 2 study in cholestatic liver diseases, which we expect to begin in the first quarter next year. Alongside that progress, we elected to share U.S. costs and profits for the HSV helicase primase inhibitor program under our collaboration with Gilead, a decision we believe represents a significant opportunity to build long-term value. With a strong financial position, we look forward to the continued expansion of our pipeline and advancement of the herpesvirus and liver disease programs through their respective Phase 2 studies.”
Jason Okazaki, chief executive officer and president of Assembly Bio
LifeVantage Corporation held its fiscal year 2027 annual meeting of stockholders on November 5, 2026. Shareholders elected six directors to the board, approved executive compensation on an advisory basis, and ratified Deloitte & Touche, LLP as the independent accounting firm for the fiscal year ending June 30, 2027.
Retail Value Inc. (RVI) declared a final liquidating distribution of $0.1435 per share, payable on December 2, 2026, to shareholders of record as of December 1, 2026. This distribution follows the company's 2022 dissolution and sale of all real estate holdings, and management does not expect to make any further distributions as it completes its wind-up process.
KLA President and CEO Richard P. Wallace Sells $10.7M of Stock
Richard P. Wallace, President and CEO, sold 72,014 shares of KLA Corp at $149.02 a share, worth $10.7M in total on Nov 10, 2026. Shares held after the trade: 634,911 (-10.2%).
Jeremy Skule, EVP, CSO, sold 2,250 shares of Nasdaq, Inc. at $108.31 a share, worth $244K in total on Nov 10, 2026. Shares held after the trade: 94,311 (-2.3%).
ENB Financial Corp reported net income of $16.6 million for the nine months ended September 30, 2026, a slight increase from $16.0 million in the prior year period. Total assets grew to $2.4 billion, driven by a significant increase in net loans to $1.69 billion, while the company also recorded a $3.7 million expense related to merger and conversion activities.
Universal Logistics Holdings reported a net income of $18.1 million for the third quarter of 2026, a significant recovery from a net loss of $117.9 million in the same period of 2025. The prior year's results were heavily impacted by a $124.4 million impairment expense, while the current period benefited from a $48.4 million gain on the disposal of property and equipment.
Interlink Electronics reported Q3 2026 revenue of $3.06 million, a 3.4% increase year-over-year, driven by higher shipments of force-sensing and gas-sensor products. The company also announced the expansion of its R&D and manufacturing footprint in the UK and Scotland to support smart textiles and medical applications. Management expects a previously announced transformative acquisition to close in Q4 2026, projecting pro forma 2026 revenue of $50 million.
Term
Q3 2026
“We continue to invest in our business and take the necessary steps to drive long-term growth. We feel confident that our existing technologies and capabilities, coupled with adding additional sales and marketing resources, will position us for organic growth in the coming years.”
Sanfilippo John B & Son Announces $20M Stock Buyback
John B. Sanfilippo & Son, Inc. announced that its Board of Directors authorized a new $20.0 million stock repurchase program for its Common Stock. Additionally, the company declared a special cash dividend of $2.00 per share, totaling approximately $24.0 million, to be paid on December 18, 2026.
TheRealReal CEO Levesque Rati Sahi Sells $1.97M of Stock
Levesque Rati Sahi, CEO, sold 133,492 shares of TheRealReal, Inc. at $14.76 a share, worth $1.97M in total on Nov 11, 2026. Shares held after the trade: 1,399,151 (-6.5%).
HeartBeam, Inc. reported a net loss of $12.7 million for the nine months ended September 30, 2026, compared to $15.7 million in the prior year period. The company remains pre-revenue and issued a going concern warning, stating that its $6.1 million in cash is insufficient to fund operations for the next twelve months.
HawkEye 360 reported Q3 2026 revenue of $59.3 million, an 84% increase year-over-year, driven by strong international growth. The company raised its full-year 2026 revenue guidance to $225-$227 million and highlighted a record backlog of $300.3 million.
Term
Q3 2026
“I am pleased with our third quarter results as we continue to see strong momentum for signals intelligence data and analytics. Importantly, growth on the international side of our business continues to gain significant traction, highlighted by revenue increasing 76% year-over-year to $23.3 million.”
John Serafini, Chief Executive Officer
“More recently, we reached another milestone in our next phase of constellation expansion with the launches of Clusters 15 and 16 in October. Following deployment, our space operations team successfully established communications with all six satellites across both clusters.”
Erasca, Inc. reported a significant increase in net loss to $278.9 million for the nine months ended September 30, 2026, primarily driven by a $150.0 million in-process research and development charge. Despite the loss, the company strengthened its balance sheet through underwritten offerings, ending the period with $947.8 million in cash, cash equivalents, and marketable securities.
NorthStar Earth & Space Enterprises, Inc. reported a net income of $2.36 million for the nine months ended September 30, 2026, primarily driven by $5.91 million in interest income from its Trust Account. The company, a former SPAC, consummated its business combination on October 1, 2026, and reported a shareholders' deficit of $11.5 million as of the quarter-end.